Sulfasalazine API Market

Sulfasalazine API Market Size, Share & Industry Analysis, By Source (Synthetic, Semi-Synthetic), By End-User (Pharmaceutical Companies, Research Institutes, CMOs), and Forecast Period 2025-2035

Sulfasalazine market is experiencing a CAGR of 6.3% during the forecast period, Growth is primarily driven by the rising global incidence of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA), conditions for which sulfasalazine is a first-line or adjunctive treatment. The market is also benefitting from its use in generic formulations, increasing demand in emerging markets, and the expansion of contract manufacturing organizations (CMOs).

Technological advancements in API synthesis processes, such as flow chemistry and solvent recovery systems, have led to improved purity and cost-effectiveness, further fueling market penetration.

Regionally, Asia-Pacific leads in API production due to cost advantages and growing pharmaceutical manufacturing capabilities in India and China. North America and Europe, however, remain key consumers, given high disease prevalence and regulatory approvals for biosimilars and generics.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Speak to an Expert

Report Scope & Segmentation

  1. Introduction
  • Overview of Sulfasalazine
  • Key End-Users & Industry Use Cases
  • Market Scope & Study Objectives
  1. Market Overview
  • Global Market Size & Growth Trends (Historical & Forecast)
  • Demand-Supply Dynamics
  1. Segmental Outlook
  • By Source
    • Petroleum-based (Derived from chemical synthesis using petrochemical precursors)
    • Bio-based (Derived from renewable sources like microbial fermentation of sugars or biomass)
  • Key End-Use Industries
  • Pharmaceuticals & Healthcare
  • Food & Beverage
  • Cosmetics & Skincare
  • Chemical & Polymer Industry
  1. Price Analysis
  • Current Price Trends (Per kg & Per Ton)
  • Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
  • Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)
  1. Trade Analysis
  • Major Exporting & Importing Countries
  • Trade Volume & Value Statistics
  • Impact of Trade Regulations & Policies
  1. Regional Analysis
  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
  • Rest of the World (Latin America, and Middle East, and Africa)
  1. Competitive Landscape
  • Top Global Manufacturers & Production Capacity
  • Company Profiles & Key Developments
    • Ipca Laboratories Ltd.
    • ZCL Chemicals Ltd.
    • Teva API
    • LGM Pharma
    • Cambrex Corporation
    • Moehs Group
    • FIS – Fabbrica Italiana Sintetici
    • Manus Aktteva Biopharma LLP
    • Taj Pharmaceuticals
    • Shouguang Fukang Pharmaceutical Co., Ltd.
    • Abbott Laboratories (via legacy brands)
    • Wuxi AppTec (CDMO)
    • Sun Pharma Advanced Research Company
    • Aarti Drugs Ltd.
    • Divi’s Laboratories
    • Granules India
    • Cipla Ltd.
    • Dr. Reddy’s Laboratories
    • Hovione
    • Jubilant Pharmova Ltd.
  • Mergers, Acquisitions & Investments
  1. Regulatory & Compliance Factors
  • FDA, REACH, and Other Regulatory Frameworks
  • Environmental & Safety Considerations
  • Emerging Policies Impacting Market Growth
  1. Conclusion & Strategic Recommendations
  • Key Takeaways for Stakeholders
  • Market Entry Strategies
Facebook Twitter Youtube
  • Frequently Asked Questions
What therapeutic class does Sulfasalazine belong to?
Sulfasalazine belongs to the anti-inflammatory and disease-modifying antirheumatic drugs (DMARDs) class, primarily used to treat rheumatoid arthritis and ulcerative colitis.
What is the global market size of the Sulfasalazine API?
The Sulfasalazine API market is estimated at over USD 150 million in 2025 and is projected to grow steadily at a CAGR of around 6.3% by 2035.
What are the major growth drivers for this market?
Increasing prevalence of inflammatory bowel diseases and rheumatoid arthritis, along with rising generic API demand, are key growth drivers.
Which companies lead the global supply of Sulfasalazine API?
Key players include Ipca Laboratories, Cadila Healthcare, Aurobindo Pharma, Sun Pharma, and Teva API, dominating global production and export.
Which region is expected to dominate or grow fastest during the forecast period?
Asia-Pacific, particularly India and China, is expected to lead due to large-scale API manufacturing and strong pharmaceutical export capabilities.
  • Choose License Type
$1800/- Single User License
$3600/- Multi User License
  • Why Choose us?
  • Experienced in market research and consulting.
  • Seasoned professionals with diverse industry knowledge.
  • Proven track record in delivering valuable insights.
  • Tailored methodologies for unique client needs.
  • End-to-end services: market analysis, competitor intelligence, consumer behavior, and strategic recommendations.
  • Latest tools and tech for data collection, analysis, and visualization.
  • Embrace of AI and machine learning for deeper insights.
  • Global capabilities and extensive network.
  • In-depth understanding of international markets, trends, and regulations.
  • Dedicated to addressing specific client needs and goals.
  • Focus on delivering value through efficient research outcomes.
  • Recent posts

How can we help you?

Reach out to discuss how our team can help your business achieve real results.

Contact Person

Mr. Anurag Tiwari

Call Us

+91-780-304-0404

Mail Us

info@omrglobal.com

Linkedin Twitter Facebook

How To Order | Delivery Method | Return Policy | Terms of uses | Privacy Policy | FAQs